Candidate Compounds Covid19

(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
K
(46 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt)
Zeile 1: Zeile 1:
 
{{pnc}}
 
{{pnc}}
 +
{{ft|P}}
 +
...so calm down and enjoy the progress of immediate translational medicine:
 +
A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
 +
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
 +
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
 +
Paper is (not yet in PubMed) :
  
current items will be put into the subsections.
+
*'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]'''
subsections with contents are marked ''with content''.
+
credentials to [https://web.de/magazine/news/coronavirus/coronavirus-blockade-zellulaerer-kommunikation-forscher-stoppen-vermehrung-sars-cov-2-35045170 Marinus Brandl] who told us about it today.
the others are pending data.
+
based on e.g.
  
*[[reviews on covid drug development]] ''with content''
+
{{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}}
*
+
 
 +
=======================================================================================
 +
 
 +
COVID19 is now a CURABLE disease !!!
 +
 
 +
=======================================================================================
 +
 
 +
*[[reviews on covid drug development]]  
 +
*[[scouting ideas]]
  
 
*[[Patients on biologicals]]
 
*[[Patients on biologicals]]
 
*[[HMGB1, RAGE]]
 
*[[HMGB1, RAGE]]
*[[pre-Interleukin 6]] ''with content''
+
*[[pre-Interleukin 6]]  
 
*[[post-Interleukin 6]]
 
*[[post-Interleukin 6]]
 
*[[pre-TNFalpha]]
 
*[[pre-TNFalpha]]
Zeile 18: Zeile 32:
 
*[[pre-Interleukin 1]]
 
*[[pre-Interleukin 1]]
 
*[[post-Interleukin 1]]
 
*[[post-Interleukin 1]]
*[[Inflammasome]]
+
*[[Inflammasome]] ''colchicine''
 
+
*[[Methotrexate]]
 +
*[[other anti-inflammatory]]
 
*[[NK-kappaB]]
 
*[[NK-kappaB]]
 
*[[STAT 3]]
 
*[[STAT 3]]
Zeile 27: Zeile 42:
 
*[[Target Complement system]]
 
*[[Target Complement system]]
 
*[[Target Extracellular traps]]
 
*[[Target Extracellular traps]]
 +
*[[Caplacizumab]] vWF(TTP)
 +
*[[Target Neurophils]]
 +
*[[Target Mast cells]] and kinins
 +
*[[TGF beta]]
 +
*[[Immunosuppressants]]
 
*[[Anticoagulant in covid19]]
 
*[[Anticoagulant in covid19]]
 
*[[Antioxidants]]
 
*[[Antioxidants]]
 +
*[[HIF-EPO-Iron]]
 
*[[Stem cells]]
 
*[[Stem cells]]
 
*[[MDSC cells]]
 
*[[MDSC cells]]
 
+
*[[Interferons]]
 +
*[[cAMP cGMP PDE NO]]
 +
*[[TRPV* channels]]
 +
*[[Retinoids]]
 +
*[[Protease inhibitors]]
 +
*[[Tyrosine kinase inhibitors]]
 +
*[[Antineoplastic agents, traditional]]
 +
*[[Mouthrinses]]
 +
*[[Adenosinergic signaling]]
 +
*[[Purinergic signaling]]
 +
*[[Nicotinergic signaling]]
  
  
 
*[[other single compounds]]
 
*[[other single compounds]]
*[[Retargeted single compounds]]
+
*[[Retargeted Psychopharm]]
*[[Hydroxychloroquine]] ''with content''
+
*[[Hydroxychloroquine]]  
 
*
 
*
 
+
*[[Target ACE2, Spike protein]]
 +
*[[Target TMPRSS2, Spike protein]] ''any other covid targed herein''
 +
*[[Aprotinin]] protease inh bradykinin synth. inh.
 
*[[other antiviral compounds]]
 
*[[other antiviral compounds]]
 
*[[AV Remdesivir]]
 
*[[AV Remdesivir]]
 
*[[AV Lopinavir]]
 
*[[AV Lopinavir]]
 
*[[AV Ivermectin]]
 
*[[AV Ivermectin]]
 +
*[[AV Arabidol]]
 +
*[[AV Favipiravir]]
  
*[[Target ACE2, Spike protein]]
+
*[[Antibiotics]]
*[[Target TMPRSS2, Spike protein]]
+
 
+
 
+
 
+
*[[Interferons]]
+
 
+
  
  
 
*[[Vitamin D]]
 
*[[Vitamin D]]
 
*[[Statins]]
 
 
*[[Anorganic nutrients Magnesium]]
 
*[[Anorganic nutrients Magnesium]]
 
*[[Anorganic nutrients Selenium]]
 
*[[Anorganic nutrients Selenium]]
 
*[[Anorganic nutrients Zinc]]
 
*[[Anorganic nutrients Zinc]]
 
+
*[[Anorganic nutrients Lithium]]
 +
*[[Anorganic nutrients Copper]]
 +
*[[Anorganic nutrients Bismuth]]
 +
*[[Nutrition, general]]
 +
*[[Exercise, Vibration]]
  
  
Zeile 65: Zeile 96:
 
*[[Natural compounds]]
 
*[[Natural compounds]]
  
*[[Reconvalescent blood products, Passive vaccine]] ''with content''
+
*[[Statins]]
 +
*[[Antidiabetic compounds, any]]
 +
*[[RSP - On RAS drugs]]
 +
*[[RSP - On NSAIDs]]
 +
 
 +
*[[Reconvalescent blood products, Passive vaccine]]  
 
*[[Plasmapheresis]]
 
*[[Plasmapheresis]]
  
 
*[[Immunodeviation]] e.g. by adjuvants or other vaccinations
 
*[[Immunodeviation]] e.g. by adjuvants or other vaccinations
*[[Active vaccine]] ''with cotent''
+
*[[Radiation therapy]]
 
+
*[[Phototherapy]]
 
+
*[[Active vaccine]]  
{{tp|p=32162456|t=2020. Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep  Docking of 1 3 Billion Compounds |pdf=|usr=}}
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
'''Microbiome as target'''
+
{{tp|p=32356654|t=ä. Considering the Effects of Microbiome and Diet on SARS-CoV-2 Infection: Nanotechnology Roles |pdf=|usr=}}
+
 
+
 
+
 
+
 
+
'''stem cells'''
+
{{tp|p=32257554|t=2020. Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia |pdf=|usr=}}
+
{{tp|p=32257537|t=2020. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients  with COVID-19 Pneumonia |pdf=|usr=}}
+
{{tp|p=32283815|t=2020. Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use |pdf=|usr=}}
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
{{tp|p=32241793|t=2020. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies |pdf=|usr=}}
+
 
+
 
+
 
+
 
+
 
+
'''CRISPR genome editing technology'''
+
{{tp|p=32353252|t=ä. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza |pdf=|usr=}}
+
 
+
'''Virus interference'''
+
{{tp|p=32071427|t=2020. Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses |pdf=|usr=}}
+
 
+
 
+
 
+
 
+
 
+
'''resilience enhancement'''
+
{{tp|p=32229705|t=2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections |pdf=|usr=}}
+
{{tp|p=32311498|t=ä. The impact of nutrition on COVID-19 susceptibility and long-term consequences |pdf=|usr=}}
+
{{tp|p=32276453|t=2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency  and Similar Future Global Health Threats |pdf=|usr=}}
+
 
+
'''psychoneuroimmunology'''
+
{{tp|p=32234338|t=ä. Using psychoneuroimmunity against COVID-19 |pdf=|usr=}}
+
 
+
 
+
 
+
 
+
'''Exercise'''
+
{{tp|p=32311497|t=ä. The immunological case for staying active during the COVID-19 pandemic |pdf=|usr=}}
+
 
+
'''Topical agents''' opening up the world of nano...
+
*[https://www.dailymail.co.uk/sciencetech/article-8315269/Commercial-mouthwash-prevent-COVID-19-transmission-scientists-say.html on mouth rinses]
+
 
+
 
+
 
+
 
+
 
+
  
 +
*[[Treatment other concepts]]
 
----
 
----
 
 
 
 
 
 
{{tp|p=32247038|t=2020. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19 |pdf=|usr=}}
 
{{tp|p=32222466|t=2020. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China |pdf=|usr=}}
 
 
 
 
 
 
{{tp|p=32266375|t=ä. Inquiring into Benefits of Independent Activation of Non-Classical Renin-Angiotensin System in the Clinical Prognosis and Reduction of COVID-19 mortality |pdf=|usr=}}
 
 
 
 
 
{{tp|p=32305181|t=ä. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection |pdf=|usr=}}
 
{{tp|p=32360083|t=ä. Modulation of Hb-O2 affinity to improve hypoxemia in COVID-19 patients |pdf=|usr=}}
 
 
{{tp|p=32277367|t=ä. Rheumatologists? perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets |pdf=|usr=}}
 
{{tp|p=32373721|t=2020. Low dose lung radiotherapy for COVID-19 pneumonia  The rationale for a cost-effective anti-inflammatory treatment |pdf=|usr=}}
 
 
 
 
 
 
 
{{tp|p=32241301|t=2020. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19 |pdf=|usr=}}
 
 
{{tp|p=32318324|t=ä. Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival |pdf=|usr=}}
 
 
 
{{tp|p=32360420|t=ä. Cytokine storm intervention in the early stages of COVID-19 pneumonia |pdf=|usr=}}
 
 
 
 
{{tp|p=32335366|t=2020. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis |pdf=|usr=}}
 
{{tp|p=32333972|t=ä. Letter to the Editor in response to the article ?COVID-19 and diabetes: Can DPP4  inhibition play a role?? |pdf=|usr=}}
 
{{tp|p=32333966|t=2020. COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications |pdf=|usr=}}
 
{{tp|p=32333969|t=ä. Response to COVID -19 and Diabetes: Can DPP4 Inhibition Play a Role? ? GLP-1 Might Play One Too |pdf=|usr=}}
 
{{tp|p=32283128|t=ä. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?|pdf=|usr=}} ''on ace2 via adam17, nfkb via dpp4''
 
 
 
 
 
 
 
 
 
{{tp|p=32325124|t=ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals |pdf=|usr=}}
 
 
 
{{tp|p=32249203|t=ä. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and  rapid translational development |pdf=|usr=}}
 
 
 
{{tp|p=32333818|t=2020. COVID-19: lambda interferon against viral load and hyperinflammation |pdf=|usr=}}
 
 
{{tp|p=32228222|t=2020. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension |pdf=|usr=}}
 
 
{{tp|p=C7118608|t=ä. A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System |pdf=|usr=}}
 
{{tp|p=32065055|t=2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody |pdf=|usr=}}
 
 
{{tp|p=32292627|t=ä. Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment |pdf=|usr=}}
 
 
 
{{tp|p=32347925|t=ä. Statin therapy in COVID-19 infection |pdf=|usr=}}
 
 
{{tp|p=32337546|t=ä. Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?|pdf=|usr=}}
 
{{tp|p=32282032|t=ä. Neprilysin inhibitor?angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients |pdf=|usr=}}
 
{{tp|p=32285293|t=ä. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV |pdf=|usr=}}
 
 
 
{{tp|p=32265310|t=ä. Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19 |pdf=|usr=}}
 
{{tp|p=32271462|t=2020. Inositol and pulmonary function  Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?|pdf=|usr=}}
 
 
 
 
 
 
 
 
{{tp|p=32329380|t=2020. Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia |pdf=|usr=}}
 
{{tp|p=32312129|t=2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic |pdf=|usr=}}
 
{{tp|p=32117569|t=2020. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China |pdf=|usr=}}
 
 
 
 
 
 
{{tp|p=32251729|t=ä. The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design |pdf=|usr=}}
 
 
 
{{tp|p=32247692|t=ä. Faecal-oral transmission of SARS-COV-2: practical implications |pdf=|usr=}}
 
{{tp|p=32367287|t=ä. New evidence of SARS-CoV-2 transmission through the ocular surface |pdf=|usr=}}
 
 
 
{{tp|p=32251365|t=ä. Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy |pdf=|usr=}}
 
 
{{tp|p=32186952|t=2020. COVID-19, an emerging coronavirus infection: advances and prospects in designing  and developing vaccines, immunotherapeutics, and therapeutics |pdf=|usr=}}
 
 
 
 
 
 
{{tp|p=32366728|t=2020. Medical Education During the COVID-19 Pandemic: A Single Institution Experience |pdf=|usr=}}
 
{{tp|p=32366726|t=2020. Management of Asthma in Children during COVID-19 Pandemic |pdf=|usr=}}
 
{{tp|p=32366725|t=2020. COVID -19 Pandemic: The Challenges for Pediatric Oncology |pdf=|usr=}}
 
 
 
 
 
 
{{tp|p=32341599|t=2020. Is Immuno-modulation the Key to COVID-19 Pandemic?|pdf=|usr=}}
 
 
 
{{tp|p=32328406|t=ä. Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains |pdf=|usr=}}
 
 
 
 
 
 
{{tp|p=32272396|t=ä. The Possible of Immunotherapy for COVID-19: a Systematic Review |pdf=|usr=}}
 
 
 
{{tp|p=32234466|t=ä. Coronavirus disease 2019 (COVID-19): current status and future perspectives |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
 
 
 
 
{{tp|p=32283177|t=ä. Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in  SARS-CoV-2 Infections |pdf=|usr=}}
 
 
 
 
 
{{tp|p=32226290|t=2020. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19 |pdf=|usr=}}
 
 
 
 
 
 
 
*[https://www.infowars.com/experts-suggest-90-million-oxford-university-coronavirus-vaccine-doesnt-work/ Oxford vaccine failed in monkeys]
 
{{tp|p=32305009|t=ä. Investigating hypothiocyanite against SARS-CoV-2 |pdf=|usr=}}
 
 
 
{{tp|p=32354030|t=2020. Functional Role of Dietary Intervention to Improve the Outcome of COVID-19: A Hypothesis of Work |pdf=|usr=}}
 
 
 
 
{{tp|p=32368489|t=2020. The pathogenesis and alternative treatment of SARS-CoV2 |pdf=|usr=}}
 
 
 
 
 
 
*[https://www.nature.com/articles/d41573-020-00073-5 Nature: The COVID-19 vaccine development landscape]
 
 
 
 
{{tp|p=32336674|t=ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research |pdf=|usr=}}
 
 
 
{{tp|p=32317220|t=ä. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19 |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
 
 
 
{{tp|p=32326602|t=2020. Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19 |pdf=|usr=}}
 
{{tp|p=32326426|t=2020. COVID-19: A Recommendation to Examine the Effect of Mouthrinses with beta-Cyclodextrin Combined with Citrox in Preventing Infection and Progression |pdf=|usr=}}
 
 
 
 
 
 
 
{{tp|p=32359878|t=2020. Application of plasma exchange in association with higher dose CVVH in Cytokine Storm Complicating COVID-19 |pdf=|usr=}}
 
 
{{tp|p=32171450|t=2020. Identification of potential cross-protective epitope between a new type of coronavirus (2019-nCoV) and severe acute respiratory syndrome virus |pdf=|usr=}}
 
 
{{tp|p=32373322|t=ä. Fighting COVID-19 with water |pdf=|usr=}}''dehydration of mucous glycans''
 
 
 
 
 
 
 
{{tp|p=32293807|t=2020. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID?19: initial assessment |pdf=|usr=}}
 
 
 
 
 
{{tp|p=32356252|t=ä. COVID-19: Therapeutics and Their Toxicities |pdf=|usr=}}
 
{{tp|p=32356251|t=ä. Medical Toxicology and COVID-19: Our Role in a Pandemic |pdf=|usr=}}
 
{{tp|p=32052466|t=2020. Potential interventions for novel coronavirus in China: A systematic review |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
 
 
{{tp|p=32346490|t=ä. Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase |pdf=|usr=}}
 
{{tp|p=32324533|t=2020. Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients |pdf=|usr=}}
 
 
{{tp|p=32291198|t=2020. Impact of Nutrition and Diet on COVID-19 Infection and Implications for Kidney Health and Kidney Disease Management |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
 
{{tp|p=32321635|t=2020. Old and new antirheumatic drugs for the treatment of COVID-19 |pdf=|usr=}}
 
 
{{tp|p=32317113|t=2020. COVID-19 therapeutic options for patients with kidney disease |pdf=|usr=}}
 
 
 
 
 
 
{{tp|p=32035018|t=2020. Reducing mortality from 2019-nCoV: host-directed therapies should be an option |pdf=|usr=}}
 
 
 
{{tp|p=32220278|t=2020. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?|pdf=|usr=}}
 
{{tp|p=32353328|t=2020. What policy makers need to know about COVID-19 protective immunity |pdf=|usr=}}
 
{{tp|p=32305088|t=2020. Flooded by the torrent: the COVID-19 drug pipeline |pdf=|usr=}}
 
 
{{tp|p=32339473|t=ä. Probiotics and COVID-19: one size does not fit all |pdf=|usr=}}
 
{{tp|p=32199468|t=ä. Use of antiviral drugs to reduce COVID-19 transmission |pdf=|usr=}}
 
{{tp|p=32278361|t=ä. Attention should be paid to venous thromboembolism prophylaxis in the management  of COVID-19 |pdf=|usr=}}
 
 
{{tp|p=32325035|t=ä. Plea for multitargeted interventions for severe COVID-19 |pdf=|usr=}}
 
{{tp|p=32113510|t=2020. Convalescent plasma as a potential therapy for COVID-19 |pdf=|usr=}}
 
{{tp|p=32113509|t=2020. COVID-19: combining antiviral and anti-inflammatory treatments |pdf=|usr=}}
 
{{tp|p=32368737|t=2020. Preventing COVID-19-induced pneumonia with anticytokine therapy |pdf=|usr=}}
 
 
 
 
 
 
 
{{tp|p=32278693|t=2020. In silico studies on therapeutic agents for COVID-19: Drug repurposing approach |pdf=|usr=}}
 
 
 
{{tp|p=32198163|t=2020. Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection |pdf=|usr=}}
 
{{tp|p=32265331|t=2020. Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein  Protects Mice from Fatal MERS-CoV Infection |pdf=|usr=}}
 
 
{{tp|p=32296777|t=2020. Mesenchymal stem cells and management of COVID-19 pneumonia |pdf=|usr=}}
 
{{tp|p=32289117|t=2020. Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus |pdf=|usr=}}
 
 
 
 
 
 
{{tp|p=32292909|t=2020. Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies |pdf=|usr=}}
 
{{tp|p=32220710|t=2020. Renin-angiotensin system: The unexpected flaw inside the human immune system revealed by SARS-CoV-2 |pdf=|usr=}}
 
 
*''riociguat?''
 
 
{{tp|p=32353740|t=2020. Serum albumin-mediated strategy for the effective targeting of SARS-CoV-2 |pdf=|usr=}}
 
 
 
 
 
 
 
 
 
{{tp|p=32344313|t=ä. Can pioglitazone be potentially useful therapeutically in treating patients with  covid-19?|pdf=|usr=}}
 
{{tp|p=32344312|t=2020. Potential effect of natural and anabolizan steroids in elderly patient with COVID-19 |pdf=|usr=}}
 
{{tp|p=32344310|t=2020. Respiratory conditions in coronavirus disease 2019 (COVID-19): Important considerations regarding novel treatment strategies to reduce mortality |pdf=|usr=}}
 
 
 
{{tp|p=32339777|t=2020. May IL-17 have a role in COVID-19 infection?|pdf=|usr=}}
 
{{tp|p=32335456|t=2020. The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?|pdf=|usr=}}
 
 
{{tp|p=C7158785|t=ä. Convalescent plasma: A possible treatment of COVID-19 in India |pdf=|usr=}}
 
{{tp|p=32353355|t=ä. Testosterone, a key hormone in the context of COVID-19 pandemic |pdf=|usr=}}
 
{{tp|p=32370766|t=2020. Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines |pdf=|usr=}}
 
{{tp|p=32307014|t=2020. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19 |pdf=|usr=}}
 
{{tp|p=32255312|t=2020. A possible probiotic (S  salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32365556|t=2020. Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-gamma as Candidates for Cytokine Storm Modulation in COVID-19 Disease |pdf=|usr=}}
 
{{tp|p=32231348|t=2020. Emerging prophylaxis strategies against COVID-19 |pdf=|usr=}}
 
 
 
{{tp|p=32187463|t=ä. Covid-19 ? The Search for Effective Therapy |pdf=|usr=}}
 
 
{{tp|p=32354113|t=2020. On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges |pdf=|usr=}}
 
{{tp|p=32326343|t=2020. Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2?|pdf=|usr=}}
 
 
{{tp|p=32203437|t=ä. Insights from nanomedicine into chloroquine efficacy against COVID-19 |pdf=|usr=}}
 
 
 
{{tp|p=32296135|t=ä. COVID-19: risk for cytokine targeting in chronic inflammatory diseases?|pdf=|usr=}}
 
{{tp|p=32355330|t=ä. Inactivated vaccine for SARS-CoV-2 |pdf=|usr=}}
 
 
{{tp|p=32346092|t=ä. Cancer therapy tool informs COVID-19 vaccines |pdf=|usr=}}
 
{{tp|p=32346094|t=ä. COVID-19 vaccine design: the Janus face of immune enhancement |pdf=|usr=}}
 
{{tp|p=32317716|t=ä. The potential danger of suboptimal antibody responses in COVID-19 |pdf=|usr=}}
 
*[https://www.biorxiv.org/content/10.1101/2020.03.22.002386v3 A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing]
 
 
 
 
{{tp|p=32341531|t=ä. Could BCG be used to protect against COVID-19?|pdf=|usr=}}
 
{{tp|p=32291449|t=ä. ADAM17 inhibition may exert a protective effect on COVID-19 |pdf=|usr=}}
 
{{tp|p=32350818|t=ä. Chloroquine-induced QTc prolongation in COVID-19 patients |pdf=|usr=}}
 
*[https://theconversation.com/we-found-and-tested-47-old-drugs-that-might-treat-the-coronavirus-results-show-promising-leads-and-a-whole-new-way-to-fight-covid-19-136789 dextrometorphan (antitussive compd)]
 
{{tp|p=32322402|t=2020. Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19 |pdf=|usr=}}
 
{{tp|p=32355564|t=2020. Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome |pdf=|usr=}}
 
{{tp|p=32322397|t=2020. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance |pdf=|usr=}}
 
{{tp|p=32313660|t=2020. A short review on antibody therapy for COVID-19 |pdf=|usr=}}
 
{{tp|p=32372835|t=2020. Trials of BCG vaccine will test for covid-19 protection |pdf=|usr=}}
 
{{tp|p=32287799|t=2020. Drug trials under way |pdf=|usr=}}
 
{{tp|p=32353120|t=ä. Does Cigarette Smoking Protect Against SARS-CoV-2 Infection?|pdf=|usr=}}
 
{{tp|p=32242236|t=ä. COVID-19 and Smoking |pdf=|usr=}}
 
{{tp|p=32194995|t=2020. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines |pdf=|usr=}}
 
{{tp|p=32340216|t=2020. Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections |pdf=|usr=}}
 
{{tp|p=32252338|t=2020. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths |pdf=|usr=}}
 
{{tp|p=32342019|t=ä. Exercise against SARS-CoV-2 (COVID-19): Does workout intensity matter? (A mini review of some indirect evidence related to obesity) |pdf=|usr=}}
 
{{tp|p=32258351|t=2020. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses |pdf=|usr=}}
 
{{tp|p=32258207|t=2020. High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019 |pdf=|usr=}}
 
{{tp|p=32363212|t=ä. Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19) |pdf=|usr=}}
 
{{tp|p=32292817|t=2020. Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19 |pdf=|usr=}}
 
{{tp|p=32284951|t=2020. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options |pdf=|usr=}}
 
{{tp|p=32214286|t=2020. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use |pdf=|usr=}}
 
{{tp|p=32098302|t=2020. Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development |pdf=|usr=}}
 
{{tp|p=32357471|t=2020. Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs |pdf=|usr=}}
 
{{tp|p=32333199|t=ä. Coronavirus in Hematologic Malignancies: Targeting Molecules Beyond the Angiotensin-Converting Enzyme 2 (ACE2) Wall in COVID-19 |pdf=|usr=}}
 
{{tp|p=32307559|t=ä. Management for patients with pediatric surgical disease during the COVID-19 epidemic |pdf=|usr=}}
 
{{tp|p=32215760|t=2020. Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond |pdf=|usr=}}
 
{{tp|p=32245264|t=2020. Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses |pdf=|usr=}}
 
{{tp|p=32290348|t=2020. COVID-19: A Brief Overview of the Discovery Clinical Trial |pdf=|usr=}}
 
{{tp|p=32371086|t=ä. The pros and cons of traditional Chinese medicines in the treatment of COVID-19 |pdf=|usr=}}
 
{{tp|p=32145402|t=2020. Traditional Chinese medicine for COVID-19 treatment |pdf=|usr=}}
 
{{tp|p=32205232|t=2020. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) |pdf=|usr=}}
 
{{tp|p=32360585|t=ä. Current targeted therapeutics against COVID-19: based on first-line experience in china |pdf=|usr=}}
 
{{tp|p=32360584|t=ä. Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2 |pdf=|usr=}}
 
{{tp|p=32360583|t=ä. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis |pdf=|usr=}}
 
{{tp|p=32360581|t=ä. Nitazoxanide/Azithromycin combination for COVID-19: A suggested new protocol for  COVID-19 early management |pdf=|usr=}}
 
{{tp|p=32360580|t=ä. Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-kappaB signaling pathway |pdf=|usr=}}
 
{{tp|p=32251726|t=2020. The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm  than good |pdf=|usr=}}
 
{{tp|p=32251725|t=ä. Reply to ?The use of traditional Chinese medicines to treat SARS-CoV-2 may cause  more harm than good? |pdf=|usr=}}
 
{{tp|p=32360484|t=2020. Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico  and experimental study |pdf=|usr=}}
 
{{tp|p=32360480|t=ä. Candidate drugs against SARS-CoV-2 and COVID-19 |pdf=|usr=}}
 
{{tp|p=32334052|t=2020. Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection |pdf=|usr=}}
 
{{tp|p=32325127|t=2020. Darunavir does not prevent SARS-CoV-2 infection in HIV patients |pdf=|usr=}}
 
{{tp|p=32247821|t=2020. 3CLpro inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials |pdf=|usr=}}
 
{{tp|p=32302707|t=ä. Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?: This paper is dedicated to  Sofia Maione born during COVID-19 outbreak |pdf=|usr=}}
 
{{tp|p=32283223|t=2020. Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19) |pdf=|usr=}}
 
{{tp|p=32322486|t=2020. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome |pdf=|usr=}}
 
{{tp|p=32369479|t=2020. Antibody-based therapies for COVID-19: Can Europe move faster?|pdf=|usr=}}
 
{{tp|p=32343686|t=2020. Pandemic responses: Planning to neutralize SARS-CoV-2 and prepare for future outbreaks |pdf=|usr=}}
 
 
{{tp|p=32054787|t=2020. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection |pdf=|usr=}}
 
{{tp|p=32253318|t=2020. Effectiveness of convalescent plasma therapy in severe COVID-19 patients |pdf=|usr=}}
 
{{tp|p=32229574|t=2020. News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine |pdf=|usr=}}
 
{{tp|p=32275753|t=ä. Plasminogen improves lung lesions and hypoxemia in patients with COVID-19 |pdf=|usr=}}
 
{{tp|p=32342871|t=ä. Is low dose radiation therapy a potential treatment for COVID-19 pneumonia?|pdf=|usr=}}
 
{{tp|p=32342874|t=ä. Low dose radiation therapy for COVID-19 pneumonia: a double-edged sword |pdf=|usr=}}
 
{{tp|p=32327397|t=ä. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine |pdf=|usr=}}
 
{{ttp|p=32322478|t=2020. Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases |pdf=|usr=}}
 
{{tp|p=32354685|t=ä. Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia |pdf=|usr=}}
 
 
{{tp|p=32239125|t=2020. Remdesivir, la esperanza antiviral frente al SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32256547|t=2020. Clinical trials on drug repositioning for COVID-19 treatment |pdf=|usr=}}
 
{{tp|p=32267301|t=ä. Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes |pdf=|usr=}}
 
{{tp|p=32232552|t=ä. Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs |pdf=|usr=}}
 
{{tp|p=32124179|t=ä. Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need |pdf=|usr=}}
 
{{tp|p=32376987|t=2020. Inhibition of Influenza A virus propagation by benzoselenoxanthenes stabilizing TMPRSS2 Gene G-quadruplex and hence down-regulating TMPRSS2 expression |pdf=|usr=}}
 
{{tp|p=32278175|t=ä. COVID-19: A promising cure for the global panic |pdf=|usr=}}
 
{{tp|p=32253226|t=ä. (β-D-N4-hydroxycytidine (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice |pdf=|usr=}}
 
{{tp|p=32358203|t=ä. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir |pdf=|usr=}}
 
{{tp|p=32198291|t=2020. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved ?-ketoamide inhibitors |pdf=|usr=}}
 
{{tp|p=32321856|t=ä. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease |pdf=|usr=}}
 
{{tp|p=32347055|t=2020.  Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors  |pdf=|usr=}}
 
{{tp|p=32341331|t=2020. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia |pdf=|usr=}}
 
{{tp|p=32347054|t=2020.  Strategies for vaccine development of COVID-19  |pdf=|usr=}}
 
{{tp|p=32133159|t=2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia |pdf=|usr=}}
 
{{tp|p=32366290|t=2020. Mesenchymal stem cells as a potential therapy for COVID-19 |pdf=|usr=}}
 
{{tp|p=C7110269|t=ä. COVID-19 Outbreak: an Update on Therapeutic Options |pdf=|usr=}}
 
{{tp|p=32307653|t=ä. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement |pdf=|usr=}}
 
{{tp|p=32281052|t=ä. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future |pdf=|usr=}}
 
{{tp|p=32320535|t=2020. Mesenchymal stem cells as a potential treatment for critically ill patients with  coronavirus disease 2019 |pdf=|usr=}}
 
{{tp|p=32362735|t=ä. Insights into the inhibitory potential of selective phytochemicals against Mpro of 2019-nCoV: a computer-aided study |pdf=|usr=}}
 
{{tp|p=32347963|t=2020. An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19 |pdf=|usr=}}
 
{{tp|p=32343358|t=2020. Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save lives - current situation and perspectives |pdf=|usr=}}
 
{{tp|p=32328234|t=2020. Does the direct renin inhibitor have a role to play in attenuating severity of the outbreak coronavirus disease 2019 (COVID-19)?|pdf=|usr=}}
 
{{tp|p=32360140|t=ä. Bee venom and SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32345485|t=ä. Treatment for emerging viruses: Convalescent plasma and COVID-19 |pdf=|usr=}}
 
{{tp|p=32359789|t=ä. COVID-19 Convalescent Plasma: Now Is the Time for Better Science |pdf=|usr=}}
 
{{tp|p=32359788|t=ä. Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic |pdf=|usr=}}
 
{{tp|p=32289548|t=2020. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study |pdf=|usr=}}
 
{{tp|p=32247925|t=ä. Repurposing antimalarials and other drugs for COVID-19 |pdf=|usr=}}
 
{{tp|p=32145386|t=ä. Remdesivir as a possible therapeutic option for the COVID-19 |pdf=|usr=}}
 
{{tp|p=32334088|t=ä. SARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies?|pdf=|usr=}}
 
{{tp|p=32325121|t=ä. Tocilizumab: A new opportunity in the possible therapeutic arsenal against COVID-19 |pdf=|usr=}}
 
{{tp|p=32247927|t=ä. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19:  An evaluation of the evidence |pdf=|usr=}}
 
{{tp|p=32249063|t=ä. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses |pdf=|usr=}}
 
{{tp|p=32362491|t=ä. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses: (Trends in Immunology 41, 355?359; 2020) |pdf=|usr=}}
 
{{tp|p=32294562|t=ä. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease |pdf=|usr=}}
 
{{tp|p=32371057|t=ä. Potential applications of plant biotechnology against SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32291112|t=ä. Ongoing Clinical Trials for the Management of the COVID-19 Pandemic |pdf=|usr=}}
 
{{tp|p=32299202|t=2020. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs|pdf=|usr=}}
 
{{tp|p=32293834|t=2020. Antiviral treatment of COVID-19|pdf=|usr=}}
 
{{tp|p=32295153|t=2020. What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?|pdf=|usr=}}
 
{{tp|p=32235387|t=2020. Progress and Prospects on Vaccine Development against SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32034638|t=ä. Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury |pdf=|usr=}}
 
{{tp|p=32297156|t=ä. Computational Identification of Small Interfering RNA Targets in SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32360300|t=ä. Natural product-derived phytochemicals as potential agents against coronaviruses: a review |pdf=|usr=}}
 
{{tp|p=32363219|t=ä. Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock |pdf=|usr=}}
 
{{tp|p=32106567|t=2020. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies |pdf=|usr=}}
 
{{tp|p=32098094|t=2020. Structural Basis for Inhibiting Porcine Epidemic Diarrhea Virus Replication with  the 3C-Like Protease Inhibitor GC376 |pdf=|usr=}}
 
{{tp|p=32272550|t=2020. Antiviral Agents: Discovery to Resistance |pdf=|usr=}}
 
{{tp|p=32268515|t=2020. In Silico Discovery of Candidate Drugs against Covid-19 |pdf=|usr=}}
 
{{tp|p=32357553|t=2020. Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19 |pdf=|usr=}}
 
{{tp|p=32340120|t=2020. Shedding Light on the Effect of Natural Anti-Herpesvirus Alkaloids on SARS-CoV-2: A Treatment Option for COVID-19 |pdf=|usr=}}
 
{{tp|p=32295237|t=2020. Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions with Antiviral Drugs |pdf=|usr=}}
 
{{tp|p=32313883|t=2020. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review) |pdf=|usr=}}
 
{{tp|p=C7118592|t=ä. Understanding of guidance for acupuncture and moxibustion interventions on COVID-19 (Second edition) issued by CAAM |pdf=|usr=}}
 
{{ttp|p=32312290|t=2020. Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis |pdf=|usr=}}
 
 
{{tp|p=32377965|t=ä. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality |pdf=|usr=}}
 
{{tp|p=32297520|t=2020. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?|pdf=|usr=}}
 
{{tp|p=32297519|t=2020. COVID-19 and vitamin D?Is there a link and an opportunity for intervention?|pdf=|usr=}}
 
{{tp|p=32191676|t=2020. Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity?|pdf=|usr=}}
 
{{tp|p=32286694|t=2020. Letter: Covid-19, and vitamin D  Authors  reply |pdf=|usr=}}
 
{{tp|p=32281109|t=2020. Letter: Covid-19, and vitamin D |pdf=|usr=}}
 
{{tp|p=32339299|t=2020. Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic?|pdf=|usr=}}
 
{{tp|p=32330314|t=2020. Is BCG vaccination affecting the spread and severity of COVID-19?|pdf=|usr=}}
 
{{tp|p=32349517|t=2020. Becoming a Faithful Defender: Traditional Chinese Medicine against Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
 
{{tp|p=32164424|t=2020. COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic  Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease |pdf=|usr=}}
 
{{tp|p=32358817|t=2020. Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle  cell disease and acute chest syndrome |pdf=|usr=}}
 
{{tp|p=32282956|t=2020. Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle  cell patient successfully treated with tocilizumab |pdf=|usr=}}
 
{{tp|p=32247518|t=2020. COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern?|pdf=|usr=}}
 
{{tp|p=32207983|t=2020. Covid-19 infection and mortality: a physiologist?s perspective enlightening clinical features and plausible interventional strategies |pdf=|usr=}}
 
{{tp|p=32314704|t=2020. Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency |pdf=|usr=}}
 
{{tp|p=32359210|t=2020. Clinical Course of COVID-19 in a Liver Transplant Recipient on Hemodialysis and Response to Tocilizumab Therapy: A Case Report |pdf=|usr=}}
 
{{tp|p=32324331|t=2020. COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine |pdf=|usr=}}
 
{{tp|p=32274985|t=2020. Novel Coronavirus Disease (COVID-19): The Need for Immunoprevention at Industrial Scale |pdf=|usr=}}
 
{{tp|p=32352178|t=2020. Editorial: low population mortality from COVID-19 in countries south of latitude  35 degrees North-supports vitamin D as a factor determining severity  Authors  reply |pdf=|usr=}}
 
{{tp|p=32311755|t=2020. Editorial: low population mortality from COVID-19 in countries south of latitude  35 degrees North supports vitamin D as a factor determining severity |pdf=|usr=}}
 
 
{{tp|p=32329159|t=2020. Thoughts on What Chemists Can Contribute to Fighting SARS-CoV-2 - A Short Note on Hand Sanitizers, Drug Candidates and Outreach |pdf=|usr=}}
 
{{tp|p=32376597|t=2020. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series |pdf=|usr=}}
 
{{tp|p=32345616|t=2020. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19 |pdf=|usr=}}
 
{{tp|p=32304395|t=2020. COVID-19 Respiratory Failure: Targeting Inflammation on VV-ECMO Support |pdf=|usr=}}
 
{{ttp|p=32349115|t=ä. Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19 |pdf=|usr=}}
 
{{tp|p=32380318|t=ä. Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection |pdf=|usr=}}
 
{{tp|p=32380316|t=ä. Convalescent plasma in Covid-19: Possible mechanisms of action |pdf=|usr=}}
 
{{tp|p=32380315|t=ä. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis |pdf=|usr=}}
 
{{tp|p=32376396|t=ä. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk  for candidemia?|pdf=|usr=}}
 
{{tp|p=32376395|t=ä. SARS-CoV-2 infection among patients with systemic autoimmune diseases |pdf=|usr=}}
 
{{ttp|p=32376392|t=ä. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions |pdf=|usr=}}
 
{{tp|p=32376403|t=ä. Imatinib might constitute a treatment option for lung involvement in COVID-19 |pdf=|usr=}}
 
{{ttp|p=32376394|t=ä. Immunomodulatory therapy for the management of severe COVID-19  Beyond the anti-viral therapy: A comprehensive review |pdf=|usr=}}
 
{{ttp|p=32376397|t=ä. Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view |pdf=|usr=}}
 
{{tp|p=32376398|t=ä. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in  Brescia, Italy |pdf=|usr=}}
 
{{tp|p=32361195|t=ä. SARS-CoV-2 infection complicated by inflammatory syndrome  Could high-dose human  immunoglobulin for intravenous use (IVIG) be beneficial?|pdf=|usr=}}
 
{{tp|p=32304139|t=ä. Progress and Concept for COVID?19 Vaccine Development |pdf=|usr=}}
 
{{tp|p=32213152|t=2020. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?|pdf=|usr=}}
 
{{tp|p=32299796|t=2020. Antirheumatic agents in covid-19: is IL-6 the right target?|pdf=|usr=}}
 
{{ttp|p=32376613|t=2020. Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor Alisporivir (Debio 025) |pdf=|usr=}}
 
{{tp|p=32366720|t=2020. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved  drugs |pdf=|usr=}}
 
{{tp|p=32312781|t=2020. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19 |pdf=|usr=}}
 
{{tp|p=32205349|t=2020. Updated Approaches against SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32229155|t=2020. Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?|pdf=|usr=}}
 
{{tp|p=32339387|t=2020. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin |pdf=|usr=}}
 
{{tp|p=32282033|t=2020. Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic |pdf=|usr=}}
 
{{tp|p=32362106|t=2020. Management of conjunctivitis during the COVID-19 pandemic 2020 |pdf=|usr=}}
 
{{tp|p=32302379|t=2020. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients |pdf=|usr=}}
 
{{tp|p=32366511|t=2020. Developing a vaccine for covid-19 |pdf=|usr=}}
 
{{tp|p=32357949|t=2020. Covid-19: Remdesivir is helpful but not a wonder drug, say researchers |pdf=|usr=}}
 
{{tp|p=32217607|t=2020. Covid-19: what treatments are being investigated?|pdf=|usr=}}
 
{{tp|p=32217555|t=2020. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients |pdf=|usr=}}
 
{{tp|p=32209549|t=2020. Covid-19: trials of four potential treatments to generate "robust data" of what works |pdf=|usr=}}
 
{{tp|p=32340998|t=2020. Covid-19: What do we know so far about a vaccine?|pdf=|usr=}}
 
{{tp|p=32321732|t=2020. Remdesivir in covid-19 |pdf=|usr=}}
 
{{tp|p=32359080|t=2020. Off-target ACE2 ligands: Possible therapeutic option for CoVid-19?|pdf=|usr=}}
 
{{tp|p=32304110|t=2020. Dosing will be a key success factor in repurposing antivirals for COVID-19 |pdf=|usr=}}
 
{{ttp|p=32369628|t=2020. Convalescent donor SARS-COV-2-specific cytotoxic T lymphocyte infusion as a possible treatment option for COVID-19 patients with severe disease has not received enough attention till date |pdf=|usr=}}
 
{{tp|p=32369612|t=2020. Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma |pdf=|usr=}}
 
{{tp|p=32368792|t=2020. Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2 |pdf=|usr=}}
 
{{ttp|p=32358833|t=2020. A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development  IUPHAR Review 29 |pdf=|usr=}}
 
{{tp|p=32329520|t=2020. Current pharmacological treatments for COVID-19: What s next?|pdf=|usr=}}
 
{{tp|p=32371479|t=2020. Cytokine Storm Drugs Move from CAR T to COVID-19 |pdf=|usr=}}
 
{{tp|p=32303509|t=2020. Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19 |pdf=|usr=}}
 
{{tp|p=32276929|t=2020. TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?|pdf=|usr=}}
 
{{ttp|p=32324951|t=2020. Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics |pdf=|usr=}}
 
{{tp|p=32245590|t=2020. Traditional Chinese Medicine: an effective treatment for 2019 novel coronavirus pneumonia (NCP) |pdf=|usr=}}
 
 
{{tp|p=32379692|t=ä. Traditional Chinese Medicine treatment of COVID-19 |pdf=|usr=}}
 
{{tp|p=32379639|t=2020. Herbal medicine for treatment of children diagnosed with COVID-19: A review of guidelines |pdf=|usr=}}
 
{{ttp|p=32271624|t=2020. Will Complement Inhibition be the New Target in Treating COVID-19 Related Systemic Thrombosis?|pdf=|usr=}}
 
{{tp|p=32333649|t=2020. The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene |pdf=|usr=}}
 
{{tp|p=32378737|t=2020. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of  COVID-19 |pdf=|usr=}}
 
{{tp|p=32356569|t=2020. Challenges in Drug Development Posed by the COVID-19 Pandemic: An Opportunity for Clinical Pharmacology |pdf=|usr=}}
 
{{tp|p=32246834|t=2020. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection |pdf=|usr=}}
 
{{tp|p=32350860|t=2020. Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32348551|t=2020. Response to: Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An  Integrative Modeling Approach for Effective Drug Repurposing: Quantitative Clinical Pharmacology Input to SARS-CoV-2 Therapeutics Should Be Based on Robust  Data |pdf=|usr=}}
 
{{tp|p=32302411|t=2020. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and  Use in COVID-19 |pdf=|usr=}}
 
{{tp|p=32167153|t=2020. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?|pdf=|usr=}}
 
{{tp|p=32345063|t=2020. Truncated IV acetylcysteine treatment duration has potential to safely preserve resources during the COVID-19 pandemic |pdf=|usr=}}
 
{{tp|p=32315229|t=2020. COVID-19 and the CRISPR Community Response |pdf=|usr=}}
 
{{tp|p=32321407|t=2020. Hispidin and Lepidine E: two Natural Compounds and Folic acid as Potential Inhibitors of 2019-novel coronavirus Main Protease (2019-nCoVMpro), molecular docking and SAR study |pdf=|usr=}}
 
{{ttp|p=32297571|t=2020. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus|pdf=|usr=}}
 
{{tp|p=32334502|t=2020. The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral  Treatment|pdf=|usr=}}
 
{{tp|p=32133962|t=2020. Effective Chemicals against Novel Coronavirus (COVID-19) in China |pdf=|usr=}}
 
{{tp|p=32314492|t=ä. Doxycycline, a widely used antibiotic in dermatology with a possible anti?inflammatory action against IL?6 in COVID?19 outbreak |pdf=|usr=}}
 
{{tp|p=32237190|t=ä. What does androgenetic alopecia have to do with COVID?19? An insight into a potential new therapy |pdf=|usr=}}
 
{{tp|p=32227357|t=ä. COVID?19 treatment by repurposing drugs until the vaccine is in sight |pdf=|usr=}}
 
{{tp|p=32377559|t=ä. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus |pdf=|usr=}}
 
{{tp|p=32374010|t=2020. Are probiotics effective adjuvant therapeutic choice in patients with COVID-19?|pdf=|usr=}}
 
{{tp|p=32374009|t=2020. Potential mechanisms by which the oxygen-ozone (O2-O3) therapy could contribute to the treatment against the coronavirus COVID-19 |pdf=|usr=}}
 
{{tp|p=32369103|t=ä. Sacubitril/valsartan in COVID-19 patients: the need for trials |pdf=|usr=}}
 
{{tp|p=32373994|t=2020. Could host cell receptor alteration prevent SARS-CoV-2 viral entry? - Hype or hope |pdf=|usr=}}
 
{{tp|p=32373992|t=2020. MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment |pdf=|usr=}}
 
{{tp|p=32373991|t=2020. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking |pdf=|usr=}}
 
{{tp|p=32362193|t=2020. Quadruple therapy for asymptomatic COVID-19 infection patients |pdf=|usr=}}
 
{{tp|p=32366131|t=2020. Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine |pdf=|usr=}}
 
{{tp|p=32336007|t=2020. DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19?|pdf=|usr=}}
 
{{tp|p=32224164|t=2020. COVID-19 and diabetes: Can DPP4 inhibition play a role?|pdf=|usr=}}
 
{{tp|p=32278585|t=2020. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab |pdf=|usr=}}
 
{{ttp|p=32337769|t=2020. (tt bradykinin) Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32352361|t=2020. Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists |pdf=|usr=}}
 
{{tp|p=32359101|t=2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications |pdf=|usr=}}
 
{{tp|p=32281695|t=2020. Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases |pdf=|usr=}}
 
{{tp|p=32379896|t=2020. Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs |pdf=|usr=}}
 
{{tp|p=31690127|t=2019. Identification of novel proteolytically inactive mutations in coronavirus 3C-like protease using a combined approach |pdf=|usr=}}
 
{{tp|p=32157732|t=ä. Harnessing the immune system via Fc?R function in immune therapy: a pathway to next?gen mAbs |pdf=|usr=}}
 
 
{{tp|p=32298218|t=2020. Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19 |pdf=|usr=}}
 
{{tp|p=32317431|t=2020. Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future |pdf=|usr=}}
 
{{tp|p=32370727|t=2020. SARS-CoV-2 & Covid-19: Key-Roles of the  Renin-Angiotensin  System / Vitamin D Impacting Drug and Vaccine Developments |pdf=|usr=}}
 
{{ttp|p=32377694|t=2020. Towards effective COVID19 vaccines: Updates, perspectives and challenges (Review) |pdf=|usr=}}
 
{{tp|p=32338559|t=2020. Low dose radiation therapy for COVID-19 pneumonia: is there any supportive evidence?|pdf=|usr=}}
 
{{tp|p=32319538|t=2020. Zinc and respiratory tract infections: Perspectives for COVID19 (Review) |pdf=|usr=}}
 
{{tp|p=32310190|t=2020. Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19 |pdf=|usr=}}
 
{{tp|p=32347747|t=2020. Can melatonin reduce the severity of COVID-19 pandemic?|pdf=|usr=}}
 
{{tp|p=32268052|t=2020. Vitamin D, Covid-19 and Children |pdf=|usr=}}
 
{{tp|p=32268051|t=2020. Optimisation of Vitamin D Status for Enhanced Immuno-protection Against Covid-19 |pdf=|usr=}}
 
{{tp|p=32338164|t=2020. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective |pdf=|usr=}}
 
{{tp|p=32306860|t=2020. Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational investigations |pdf=|usr=}}
 
{{tp|p=32306822|t=2020. Peptide-like and small-molecule inhibitors against Covid-19 |pdf=|usr=}}
 
{{tp|p=32340551|t=2020. Natural products may interfere with SARS-CoV-2 attachment to the host cell |pdf=|usr=}}
 
{{tp|p=32329419|t=2020. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach |pdf=|usr=}}
 
{{tp|p=32329408|t=2020. Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease |pdf=|usr=}}
 
{{tp|p=32362235|t=2020. Understanding the binding affinity of ''noscapines'' with protease of SARS-CoV-2 for  COVID-19 using MD simulations at different temperatures |pdf=|usr=}}
 
{{tp|p=32362243|t=2020. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target |pdf=|usr=}}
 
{{tp|p=32364041|t=2020. Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32364011|t=2020. FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main  protease, essential for viral replication |pdf=|usr=}}
 
{{tp|p=32362217|t=2020. In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria |pdf=|usr=}}
 
{{tp|p=32362245|t=2020. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study |pdf=|usr=}}
 
{{tp|p=32345124|t=2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets |pdf=|usr=}}
 
{{tp|p=32340562|t=2020. A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32376368|t=ä. Identifying potential treatments of COVID-19 from Traditional Chinese Medicine (TCM) by using a data-driven approach |pdf=|usr=}}
 
{{tp|p=32228825|t=2020. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1 |pdf=|usr=}}
 
{{tp|p=32171193|t=2020. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by  Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies |pdf=|usr=}}
 
{{tp|p=32367767|t=2020. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL(pro)): an in silico screening of alkaloids and terpenoids from African medicinal plants |pdf=|usr=}}
 
{{tp|p=32238094|t=2020. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach |pdf=|usr=}}
 
{{tp|p=32345140|t=2020. Stilbene-based natural compounds as promising drug candidates against COVID-19 |pdf=|usr=}}
 
{{tp|p=32266867|t=2020. In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain) |pdf=|usr=}}
 
{{tp|p=32248766|t=2020. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19 |pdf=|usr=}}
 
{{tp|p=32349031|t=2020. Role of Dipeptidyl Peptidase 4 Inhibitors in Diabetic Patients with Coronavirus-19 Infection |pdf=|usr=}}
 
{{tp|p=32173110|t=2020. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 |pdf=|usr=}}
 
{{tp|p=32379348|t=2020. 3CL hydrolase-based multiepitope peptide vaccine against SARS-CoV-2 using immunoinformatics |pdf=|usr=}}
 
 
{{tp|p=32227493|t=ä. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID?19 |pdf=|usr=}}
 
{{tp|p=32219882|t=ä. Controversial treatments: An updated understanding of the coronavirus disease 2019 |pdf=|usr=}}
 
{{tp|p=32104907|t=ä. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus?A possible reference for coronavirus disease?19 treatment option |pdf=|usr=}}
 
{{tp|p=32108352|t=ä. Clinical trial analysis of 2019?nCoV therapy registered in China |pdf=|usr=}}
 
{{tp|p=32379346|t=2020. ACE2 Activators for the Treatment of Covid 19 Patients |pdf=|usr=}}
 
{{tp|p=32374457|t=2020. The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections |pdf=|usr=}}
 
{{tp|p=32369191|t=2020. Tocilizumab for the treatment of severe coronavirus disease 2019 |pdf=|usr=}}
 
{{tp|p=32356910|t=2020. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review |pdf=|usr=}}
 
{{tp|p=32232976|t=2020. CD-sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
 
{{tp|p=32176361|t=2020. Potentially repurposing adamantanes for COVID-19 |pdf=|usr=}}
 
{{tp|p=32270515|t=2020. Does recombinant human Erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?|pdf=|usr=}}
 
{{tp|p=32253759|t=2020. Tocilizumab treatment in COVID-19: A single center experience |pdf=|usr=}}
 
{{tp|p=32347974|t=2020. Metformin and COVID-19: A novel deal of an Old Drug |pdf=|usr=}}
 
{{tp|p=32239514|t=ä. Comments on Zhang et al: Clinical trial analysis of 2019?nCoV therapy registered  in China |pdf=|usr=}}
 
{{tp|p=32236562|t=2020. Treating COVID-19 with Chloroquine |pdf=|usr=}}
 
{{ttp|p=32378064|t=ä. Feasibility of Therapeutic Effects of the Cholinergic Anti-Inflammatory Pathway on COVID-19 Symptoms |pdf=|usr=}}
 
{{tp|p=32320059|t=2020. Potential of live pathogen vaccines for defeating the COVID-19 pandemic: history  and mechanism |pdf=|usr=}}
 
{{tp|p=32297988|t=2020. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis |pdf=|usr=}}
 
{{tp|p=32297985|t=2020. Evaluation of Antiviral Therapies for Coronavirus Disease 2019 (COVID-19) Pneumonia in Shanghai, China |pdf=|usr=}}
 
{{tp|p=32297987|t=2020. Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection |pdf=|usr=}}
 
{{tp|p=32293713|t=2020. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China |pdf=|usr=}}
 
{{tp|p=32285942|t=2020. Defining Protective Epitopes for COVID-19 Vaccination Models |pdf=|usr=}}
 
{{tp|p=32281679|t=2020. COVID-19: Herd Immunity and Convalescent Plasma Transfer Therapy |pdf=|usr=}}
 
{{tp|p=32302456|t=2020. Potential of heparin and nafamostat combination therapy for COVID-19 |pdf=|usr=}}
 
 
{{tp|p=32376627|t=2020. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity |pdf=|usr=}}
 
{{tp|p=32359402|t=2020. Considering BCG vaccination to reduce the impact of COVID-19 |pdf=|usr=}}
 
{{tp|p=32380023|t=ä. Immunomodulation in COVID-19 |pdf=|usr=}}
 
{{tp|p=32367857|t=2020. Safety of an immunomodulator Mycobacterium w in COVID-19 |pdf=|usr=}}
 
{{tp|p=32367847|t=2020. Nasopharyngeal wash in preventing and treating upper respiratory tract infections: Could it prevent COVID-19?|pdf=|usr=}}
 
{{tp|p=32371362|t=2020. Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients |pdf=|usr=}}
 
{{tp|p=32366816|t=2020. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development |pdf=|usr=}}
 
{{tp|p=32376359|t=ä. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32219429|t=2020. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges |pdf=|usr=}}
 
{{tp|p=32352484|t=2020. Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19 |pdf=|usr=}}
 
{{tp|p=32208486|t=2020. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical  Trials During Pandemics |pdf=|usr=}}
 
{{tp|p=32297900|t=2020. Finding Effective Treatments for COVID-19: Scientific Integrity and Public Confidence in a Time of Crisis |pdf=|usr=}}
 
{{tp|p=32282022|t=2020. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review |pdf=|usr=}}
 
{{tp|p=32347894|t=2020. The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19-First, Do No Harm |pdf=|usr=}}
 
{{tp|p=32243778|t=2020. Ensuring global access to COVID-19 vaccines |pdf=|usr=}}
 
{{tp|p=32247324|t=2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings |pdf=|usr=}}
 
{{tp|p=32251638|t=2020. Baricitinib for COVID-19: a suitable treatment?|pdf=|usr=}}
 
{{tp|p=32251639|t=2020. Baricitinib for COVID-19: a suitable treatment? - Authors  reply |pdf=|usr=}}
 
{{ttp|p=32240961|t=2020. Routine childhood immunization may protect against COVID-19 |pdf=|usr=}}
 
{{tp|p=32372435|t=2020. Drug repurposing in the era of COVID-19: a call for leadership and government investment |pdf=|usr=}}
 
{{tp|p=32266987|t=2020. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
 
{{tp|p=32324177|t=2020. Some drugs for COVID-19 |pdf=|usr=}}
 
{{tp|p=32162456|t=ä. Rapid Identification of Potential Inhibitors of SARS?CoV?2 Main Protease by Deep  Docking of 1 3?Billion Compounds |pdf=|usr=}}
 
{{tp|p=32379955|t=ä. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 |pdf=|usr=}}
 
{{tp|p=32375002|t=ä. Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery |pdf=|usr=}}
 
{{ttp|p=32378459|t=2020. Application of nanomaterials in treatment, anti-infection and detection of coronaviruses |pdf=|usr=}}
 
{{ttp|p=32363750|t=2020. A Chemographic Audit of anti-Coronavirus Structure-Activity Information from Public Databases (ChEMBL) |pdf=|usr=}}
 
{{tp|p=32369286|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19  Reply |pdf=|usr=}}
 
{{tp|p=32227757|t=2020. Developing Covid-19 Vaccines at Pandemic Speed |pdf=|usr=}}
 
{{tp|p=32289216|t=2020. Drug Evaluation during the Covid-19 Pandemic |pdf=|usr=}}
 
{{tp|p=32332765|t=2020. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig |pdf=|usr=}}
 
{{tp|p=32273604|t=2020. Lopinavir-ritonavir in severe COVID-19 |pdf=|usr=}}
 
{{tp|p=32273591|t=2020. The COVID-19 vaccine development landscape |pdf=|usr=}}
 
{{tp|p=32269311|t=2020. Coordinating the COVID-19 pipeline |pdf=|usr=}}
 
{{tp|p=32127666|t=2020. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) |pdf=|usr=}}
 
{{tp|p=32376938|t=2020. China is promoting coronavirus treatments based on unproven traditional medicines |pdf=|usr=}}
 
{{tp|p=32272481|t=2020. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors |pdf=|usr=}}
 
{{tp|p=32350436|t=2020. Hopes rise for coronavirus drug remdesivir |pdf=|usr=}}
 
{{tp|p=32355243|t=2020. Scores of coronavirus vaccines are in competition - how will scientists choose the best?|pdf=|usr=}}
 
{{tp|p=32353859|t=2020. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |pdf=|usr=}}
 
{{tp|p=32300225|t=2020. On the front lines of the coronavirus-vaccine battle |pdf=|usr=}}
 
{{tp|p=32346146|t=2020. The race for coronavirus vaccines: a graphical guide |pdf=|usr=}}
 
 
{{tp|p=32377399|t=2020. COVID-19 vaccines: breaking record times to first-in-human trials |pdf=|usr=}}
 
{{tp|p=32297843|t=2020. Oligonucleotides and the COVID-19 Pandemic: A Perspective |pdf=|usr=}}
 
{{tp|p=32380200|t=ä. In Silico Design of Antiviral Peptides Targeting the Spike Protein of SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32275178|t=2020. Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease |pdf=|usr=}}
 
{{tp|p=32216577|t=2020. Artificial intelligence and machine learning to fight COVID-19 |pdf=|usr=}}
 
{{tp|p=32380051|t=ä. The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence |pdf=|usr=}}
 
{{tp|p=32352615|t=2020. Povidone-iodine gargle as a prophylactic intervention to interrupt the transmission of SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32209313|t=2020. New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws |pdf=|usr=}}
 
{{tp|p=32285489|t=2020. Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity |pdf=|usr=}}
 
{{tp|p=32267566|t=2020. Therapeutic Potential for Tetracyclines in the Treatment of COVID-19 |pdf=|usr=}}
 
{{tp|p=32267560|t=2020. Considerations for Statin Therapy in Patients with COVID-19 |pdf=|usr=}}
 
{{tp|p=32259313|t=2020. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019 |pdf=|usr=}}
 
{{tp|p=32281114|t=2020. Delayed Initiation of Remdesivir in a COVID-19-Positive Patient |pdf=|usr=}}
 
{{tp|p=32296012|t=2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia |pdf=|usr=}}
 
{{tp|p=32295694|t=2020. COVID-19 vaccination clinical trials should consider multiple doses of BCG |pdf=|usr=}}
 
{{tp|p=32326830|t=2020. Photobiomodulation and Antiviral Photodynamic Therapy as a Possible Novel Approach in COVID-19 Management |pdf=|usr=}}
 
{{tp|p=32330404|t=2020. Can Transdermal Photobiomodulation Help Us at the Time of COVID-19?|pdf=|usr=}}
 
{{tp|p=32352594|t=2020. Phytotherapic compounds against coronaviruses: Possible streams for future research |pdf=|usr=}}
 
{{tp|p=32347602|t=2020. Should we try the antiinflammatory natural product, celastrol, for COVID-19?|pdf=|usr=}}
 
{{tp|p=32350134|t=2020. Effective treatment of severe COVID-19 patients with tocilizumab |pdf=|usr=}}
 
{{tp|p=32365207|t=ä. Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report |pdf=|usr=}}
 
{{tp|p=32314850|t=2020. Melatonin: Roles in influenza, Covid?19, and other viral infections |pdf=|usr=}}
 
{{tp|p=32374874|t=ä. COVID-19: an unexpected indication for anti-rheumatic therapies?|pdf=|usr=}}
 
{{tp|p=32376603|t=ä. Development of an inactivated vaccine candidate for SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32352871|t=2020. A Radiation Mitigator as a Potential Treatment for COVID-19 |pdf=|usr=}}
 
{{tp|p=32273254|t=2020. Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic |pdf=|usr=}}
 
{{tp|p=32167254|t=2020. Epidemie de coronavirus et polemique sur la chloroquine |pdf=|usr=}}
 
{{tp|p=32270942|t=2020. Covid-19, dans les brouillards francais de l'hydroxychloroquine |pdf=|usr=}}
 
{{tp|p=32301315|t=2020. Covid-19, dans les brouillards de l'hydroxychloroquine (2) |pdf=|usr=}}
 
{{tp|p=32301312|t=2020. Vaccins anti-covid-19 : les recherches de johnson & johnson, sanofi et pasteur |pdf=|usr=}}
 
{{tp|p=32355008|t=2020. COVID-19 shot protects monkeys |pdf=|usr=}}
 
{{tp|p=32292113|t=2020. Stem Cell?Based Therapy for Coronavirus Disease 2019 |pdf=|usr=}}
 
{{tp|p=32272857|t=2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks |pdf=|usr=}}
 
{{tp|p=32360327|t=ä. Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence |pdf=|usr=}}
 
{{tp|p=32302280|t=2020. Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department |pdf=|usr=}}
 
{{tp|p=32220178|t=2020.  Biological Product Development Strategies for Prevention and Treatment of Coronavirus Disease 2019  |pdf=|usr=}}
 
{{tp|p=32374891|t=2020. Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations  for clinical trial design |pdf=|usr=}}
 
{{tp|p=32374890|t=2020. COVID-19 convalescent plasma: phase 2 |pdf=|usr=}}
 
{{tp|p=32245869|t=2020. Possible treatment of Covid-19 with a therapeutic vaccine |pdf=|usr=}}
 
{{tp|p=32221001|t=2020. Possible method for the production of a Covid-19 vaccine |pdf=|usr=}}
 
{{tp|p=32324899|t=2020. Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy |pdf=|usr=}}
 
{{tp|p=32319102|t=2020. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma |pdf=|usr=}}
 
{{tp|p=32240545|t=2020. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?|pdf=|usr=}}
 
{{tp|p=32268018|t=2020.  Analysis of medication characteristics of traditional Chinese medicine in treating coronavirus disease-19 based on data mining  |pdf=|usr=}}
 
{{tp|p=32281335|t=2020.  Research progress of intervention of Chinese herbal medicine and its active components on human coronavirus  |pdf=|usr=}}
 
{{tp|p=32281333|t=2020.  Analysis of property and efficacy of traditional Chinese medicine in staging revention and treatment of coronavirus disease 2019  |pdf=|usr=}}
 
{{tp|p=32281332|t=2020.  Study on medication regularity of traditional Chinese medicine in treatment of COVID-19 based on data mining  |pdf=|usr=}}
 
{{tp|p=32281331|t=2020.  Analysis on pattern of prescriptions and syndromes of traditional Chinese medicine for prevention and treatment of COVID-19  |pdf=|usr=}}
 
{{tp|p=32281330|t=2020.  Analysis on clinical study protocols of traditional Chinese medicine for coronavirus disease 2019  |pdf=|usr=}}
 
{{ttp|p=32281329|t=2020.  Study on treatment of "cytokine storm" by anti-2019-nCoV prescriptions based on  arachidonic acid metabolic pathway  |pdf=|usr=}}
 
{{tp|p=32281328|t=2020.  Study on screening potential traditional Chinese medicines against 2019-nCoV based on Mpro and PLP  |pdf=|usr=}}
 
{{tp|p=32281327|t=2020.  Rapid establishment of traditional Chinese medicine prevention and treatment of  2019-nCoV based on clinical experience and molecular docking  |pdf=|usr=}}
 
{{tp|p=32164085|t=2020.  Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia  |pdf=|usr=}}
 
{{tp|p=32164084|t=2020.  Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia  |pdf=|usr=}}
 
{{tp|p=32164080|t=2020.  Potential antiviral therapeutics for 2019 Novel Coronavirus  |pdf=|usr=}}
 
{{tp|p=32164081|t=2020.  Pharmacotherapeutics for the new coronavirus pneumonia  |pdf=|usr=}}
 
{{tp|p=32164077|t=2020.  Pharmacotherapeutic about the new coronavirus pneumonia  |pdf=|usr=}}
 
{{tp|p=32114746|t=2020.  Drug interaction monitoring of lopinavir/ritonavir in COVID-19 patients with cancer  |pdf=|usr=}}
 
{{tp|p=32234130|t=2020.  Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)  |pdf=|usr=}}
 
 
{{tp|p=C7203037|t=ä. (Vitamin-C; Ozone)Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19? |pdf=|usr=}}
 
{{tp|p=C7197234|t=2020. Safety concerns with higher dosage chloroquine in COVID-19 patients |pdf=|usr=}}
 
{{tp|p=C7197245|t=2020. Antimalarial use in COVID-19 patients requires close monitoring |pdf=|usr=}}
 
{{tp|p=C7180667|t=ä. Achilles  heel of the killer virus: the highly important molecular targets for hitting SARS-CoV-2 that causes COVID-19 |pdf=|usr=}}
 
{{tp|p=C7190525|t=2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients |pdf=|usr=}}
 
{{tp|p=C7152890|t=2020. Biomimetic nanoparticles as universal influenza vaccine |pdf=|usr=}}
 
{{tp|p=C7149307|t=ä. Die Anwendung der Traditionellen Chinesischen Medizin... |pdf=|usr=}}
 
{{tp|p=C7144855|t=ä. Protocolo de diagn�stico y tratamiento para COVID-19 mediante medicina tradicional china? |pdf=|usr=}}
 
{{tp|p=32292907|t=2020. Standing out from the crowd in treating COVID-19 |pdf=|usr=}} the title has been idioted from ''Potential TRPV1 blockade to treat severe lung dysfunction in COVID-19 infection.''
 
{{tp|p=C7187737|t=ä. COVID-19 and the Rationale for Pharmacotherapy: A South African Perspective |pdf=|usr=}}
 
{{tp|p=C7167691|t=2020. (Deutsche Szene) Schutz vor und Hilfe bei Covid19 Infektionen |pdf=|usr=}}
 
{{tp|p=C7149252|t=2020. Traditionelle Chinesische Medizin ... Ein Bericht aus Wuhan... |pdf=|usr=}}
 
{{tp|p=32483554|t=ä. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19 |pdf=|usr=}}
 
{{tp|p=32377965|t=ä. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality |pdf=|usr=}}
 
{{tp|p=C7189003|t=2020. Glukokortikoide und Covid-19 |pdf=|usr=}}
 
{{tp|p=C7189010|t=2020. Biologika und Covid-19 |pdf=|usr=}}
 
{{tp|p=C7162107|t=2020. Chloroquin gegen Corona?|pdf=|usr=}}
 
{{tp|p=C7187784|t=ä. Case Study: A Patient with Asthma, Covid-19 Pneumonia and Cytokine Release Syndrome Treated with Corticosteroids and Tocilizumab |pdf=|usr=}}
 
 
{{tp|p=32387535|t=ä. Asthma, biologics, corticosteroids, and coronavirus disease 2019 |pdf=|usr=}}
 
{{ttp|p=C7197610|t=ä. Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy |pdf=|usr=}}
 
{{tp|p=C7197606|t=ä. Antibody therapies for the treatment of COVID-19 |pdf=|usr=}}
 
{{tp|p=32376396|t=2020. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk  for candidemia?|pdf=|usr=}}
 
{{tp|p=32380316|t=2020. Convalescent plasma in Covid-19: Possible mechanisms of action |pdf=|usr=}}
 
{{tp|p=32380318|t=2020. Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection |pdf=|usr=}}
 
{{tp|p=32380315|t=2020. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis |pdf=|usr=}}
 
{{tp|p=32376392|t=2020. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions |pdf=|usr=}}
 
{{tp|p=32387040|t=ä. Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?|pdf=|usr=}}
 
{{tp|p=32389697|t=ä. Plasmapheresis treatment in COVID-19?related autoimmune meningoencephalitis: Case series |pdf=|usr=}}
 
{{tp|p=32475597|t=2020. The important role of polysaccharides from a traditional Chinese medicine-Lung Cleansing and Detoxifying Decoction against the COVID-19 pandemic |pdf=|usr=}}
 
{{tp|p=32437659|t=2020. Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection |pdf=|usr=}}
 
{{ttp|p=32402856|t=2020. Could an endo-lysosomal ion channel be the Achilles heel of SARS-CoV2?|pdf=|usr=}}
 
{{ttp|p=32231345|t=ä. Inhibition of SARS-CoV-2 infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high  capacity to mediate membrane fusion |pdf=|usr=}}''Here we generated a series of lipopeptides derived from EK1 and found that EK1C4 was the most potent fusion inhibitor against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection''
 
{{tp|p=32376238|t=2020. (rev on nat.prod.pharmacophores)Plants derived therapeutic strategies targeting chronic respiratory diseases: Chemical and immunological perspective |pdf=|usr=}}
 
{{tp|p=32391065|t=2020. Traditional Chinese medicine contributes to the treatment of COVID-19 patients |pdf=|usr=}}
 
{{tp|p=32402416|t=ä. Perforacion intestinal en paciente COVID-19 en tratamiento con tocilizumab y corticoides  ... |pdf=|usr=}}
 
{{tp|p=C7186126|t=ä. Proposed use of thalidomide for the cytokine storm of COVID-19 |pdf=|usr=}}
 
{{tp|p=32379639|t=2020. Herbal medicine for treatment of children diagnosed with COVID-19: A review of guidelines |pdf=|usr=}}
 
{{tp|p=32379692|t=2020. Traditional Chinese Medicine treatment of COVID-19 |pdf=|usr=}}
 
{{tp|p=C7151553|t=2020. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles? heel conserved region to minimize probability of escape mutations and drug resistance |pdf=|usr=}}
 
 
{{tp|p=32129977|t=2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases |pdf=|usr=}}
 
{{tp|p=29115746|t=2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies |pdf=|usr=}}
 
{{tp|p=29717819|t=2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens |pdf=|usr=}}
 
{{tp|p=28945945|t=2017. Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses |pdf=|usr=}}
 
{{tp|p=32205350|t=2020. Tilorone, a Broad-Spectrum Antiviral for Emerging Viruses |pdf=|usr=}}
 
{{tp|p=21093489|t=2011. (x)Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model |pdf=|usr=}}
 
{{tp|p=20727913|t=2010. (x)Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus |pdf=|usr=}}
 
{{tp|p=16621037|t=2006. (x)Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin |pdf=|usr=}}
 
{{tp|p=31073993|t=2019. (x)Synthesis and anti?coronavirus activity of a series of 1?thia?4?azaspiro 4 5 decan?3?one derivatives |pdf=|usr=}}
 
{{tp|p=32223926|t=2020. Remdesivir attenuates high fat diet (HFD)-induced NAFLD by regulating hepatocyte  dyslipidemia and inflammation via the suppression of STING |pdf=|usr=}}
 
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335060/ Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus btu @OnlyTheGhosts]
 
{{tp|p=32285908|t=2020. Chloroquine and bafilomycin A mimic lysosomal storage disorders and impair mTORC1 signalling |pdf=|usr=}}
 
{{ttp|p=32315397|t=2020. Promoting platelets is a therapeutic option to combat severe viral infection of the lung |pdf=|usr=}}
 
{{tp|p=32243785|t=2020. Embracing the Landscape of Therapeutics |pdf=|usr=}}
 
{{ttp|p=32313209|t=ä. Chloroquine reduces Th17 cell differentiation by stimulating T-bet expression in  T cells |pdf=|usr=}}
 
{{tp|p=17806092|t=2008. Ferrocene Conjugates of Chloroquine and other Antimalarials: the Development of Ferroquine, a New Antimalarial |pdf=|usr=}}
 
{{tp|p=30993690|t=2019. Emerging viruses and current strategies for vaccine intervention |pdf=|usr=}}
 
{{tp|p=23607598|t=2013. (x)Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress  syndrome |pdf=|usr=}}
 
{{tp|p=32099652|t=2020. Frontiers in antiviral therapy and immunotherapy |pdf=|usr=}}
 
{{ttp|p=32321563|t=2020. IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome |pdf=|usr=}}
 
{{tp|p=32259744|t=2020. DNA vaccines: prime time is now |pdf=|usr=}}
 
{{tp|p=32387642|t=2020. Innovations in structure-based antigen design and immune monitoring for next generation vaccines |pdf=|usr=}}
 
{{tp|p=C7163352|t=ä. Cell-Based Therapies for COVID-19: Proper Clinical Investigations are Essential |pdf=|usr=}}
 
 
{{tp|p=32382358|t=ä. COVID-19 and Diabetes Mellitus: May Old Anti-diabetic Agents Become the New Philosopher?s Stone?|pdf=|usr=}}
 
{{tp|p=32377559|t=ä. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus |pdf=|usr=}}
 
{{tp|p=32387262|t=ä. Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment |pdf=|usr=}}
 
{{tp|p=C7194243|t=ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion |pdf=|usr=}}
 
{{tp|p=32383008|t=ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic |pdf=|usr=}}
 
{{tp|p=32344202|t=2020. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy  and vaccine development |pdf=|usr=}}
 
{{tp|p=32387014|t=ä. Repositionnement de la chlorpromazine ... |pdf=|usr=}}''psychiatric patients could be protected from severe forms of COVID-19 by their psychotropic treatments''
 
{{tp|p=C7118608|t=ä. A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System |pdf=|usr=}}
 
{{tp|p=32292529|t=2020. Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19 |pdf=|usr=}}
 
{{tp|p=32381323|t=ä. Acute hemolysis by hydroxycloroquine was observed in G6PD-deficient patient with  severe COVD-19 related lung injury |pdf=|usr=}}
 
{{tp|p=C7117595|t=ä. Drug repurposing strategies for COVID-19 |pdf=|usr=}}
 
{{tp|p=32348877|t=ä. Chemical evolution for taming the ?pathogenic kinase? PAK1 |pdf=|usr=}}
 
{{tp|p=16022774|t=2005. (+)SARS Vaccine Development |pdf=|usr=}}
 
{{tp|p=28861908|t=2017. (+)Issues in vaccinology: Present challenges and future directions |pdf=|usr=}}
 
{{tp|p=31931639|t=2020. Dapsone as treatment adjunct in ARDS |pdf=|usr=}}
 
{{tp|p=16433589|t=2006. (+)Antiviral applications of RNAi for coronavirus |pdf=|usr=}}
 
{{tp|p=32318055|t=2020. Better Epitope Discovery, Precision Immune Engineering, and Accelerated Vaccine Design Using Immunoinformatics Tools |pdf=|usr=}}
 
 
{{tp|p=32362826|t=2020. Editorial: New Advances in RNA Targeting |pdf=|usr=}}
 
{{tp|p=32201439|t=2020. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach |pdf=|usr=}}
 
{{tp|p=32298965|t=2020. Blocking drug-induced autophagy with chloroquine in HCT-116 colon cancer cells enhances DC maturation and T cell responses induced by tumor cell lysate |pdf=|usr=}}
 
{{tp|p=32081774|t=2020. Discovery and development of safe-in-man broad-spectrum antiviral agents |pdf=|usr=}}
 
{{tp|p=32380291|t=ä. Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019 |pdf=|usr=}}
 
{{tp|p=32387130|t=ä. GTS-21, an alpha7nAChR agonist, suppressed the production of key inflammatory mediators by PBMCs that are elevated in COPD patients and associated with impaired lung function |pdf=|usr=}}
 
{{tp|p=C7184982|t=ä. Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given |pdf=|usr=}}
 
{{ttp|p=32389720|t=ä. Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin |pdf=|usr=}}
 
{{tp|p=32389721|t=ä. Tocilizumab in COVID-19: Beware the risk of intestinal perforation |pdf=|usr=}}
 
{{tp|p=32294495|t=ä. Chloroquine as a prophylactic agent against COVID-19?|pdf=|usr=}}
 
{{tp|p=32386655|t=2020. Influence of immune aging on vaccine responses |pdf=|usr=}}
 
{{tp|p=32376368|t=2020. Identifying potential treatments of COVID-19 from Traditional Chinese Medicine (TCM) by using a data-driven approach |pdf=|usr=}}
 
{{tp|p=32451138|t=ä. ...surveillance ophtalmologique ...hydroxychloroquine e... |pdf=|usr=}}
 
{{tp|p=32446813|t=ä. Diagnosis and treatment of novel coronavirus pneumonia based on the theory of traditional Chinese medicine |pdf=|usr=}}
 
 
{{tp|p=32277065|t=2020. Halting coronavirus polymerase |pdf=|usr=}}
 
{{tp|p=32336762|t=2012. Design of Angiotensin?converting Enzyme 2 (ACE2) Inhibitors by Virtual Lead Optimization and Screening |pdf=|usr=}}
 
{{tp|p=32281318|t=2020. Convalescent Plasma Therapy for Corona Virus Disease 2019: a Long Way to Go but Worth Trying |pdf=|usr=}}
 
{{tp|p=32045235|t=ä. ?-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment |pdf=|usr=}}
 
{{tp|p=32105468|t=2020. Structure-Based Stabilization of Non-native Protein?Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design |pdf=|usr=}}
 
{{tp|p=27905101|t=2017. (+)A review on antiviral activity of the Himalayan medicinal plants traditionally used to treat bronchitis and related symptoms |pdf=|usr=}}
 
{{tp|p=16697221|t=2006. (+)Template-based coiled-coil antigens elicit neutralizing antibodies to the SARS-coronavirus |pdf=|usr=}}
 
{{ttp|p=31856018|t=2020. Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome?|pdf=|usr=}}
 
{{tp|p=32388486|t=2020. Light as a potential treatment for pandemic coronavirus infections: A perspective |pdf=|usr=}}
 
{{tp|p=C7154570|t=2020. Anti-IL6R role in treatment of COVID-19-related ARDS |pdf=|usr=}}
 
{{tp|p=32423584|t=2020. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial |pdf=|usr=}}
 
{{tp|p=32423580|t=2020. Remdesivir for COVID-19: challenges of underpowered studies |pdf=|usr=}}
 
 
{{tp|p=C7202831|t=ä. Testing COVID-19 therapies to prevent progression of mild disease |pdf=|usr=}}
 
{{tp|p=C7202844|t=ä. Vaccine development during global epidemics: the Zika experience |pdf=|usr=}}
 
{{tp|p=32380023|t=ä. Immunomodulation in COVID-19 |pdf=|usr=}}
 
{{tp|p=32444269|t=ä. Immunotherapies for COVID-19: lessons learned from sepsis |pdf=|usr=}}
 
{{tp|p=32409074|t=2020. An overview of functional nanoparticles as novel emerging antiviral therapeutic agents |pdf=|usr=}}
 
{{tp|p=C7190528|t=ä. Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof) |pdf=|usr=}}
 
{{tp|p=32386744|t=ä. Uso de antipaludicos (antimalarials)...|pdf=|usr=}}
 
{{tp|p=32408073|t=2020. Lithium for the 2019 novel coronavirus |pdf=|usr=}}
 
{{tp|p=32416413|t=2020. Covid-19 management with inflammation resolving mediators? Perspectives and potential |pdf=|usr=}}
 
{{tp|p=32408070|t=2020. Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win todays battle against COVID-19?|pdf=|usr=}}
 
{{tp|p=32373787|t=2020. A new paradigm for drug development |pdf=|usr=}}
 
{{tp|p=32359447|t=2020. The resurgence of convalescent plasma therapy |pdf=|usr=}}
 
{{tp|p=32325038|t=ä. (+)Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial |pdf=|usr=}}
 
{{tp|p=32325036|t=ä. Two Middle East respiratory syndrome vaccines: first step for other coronavirus vaccines?|pdf=|usr=}}
 
{{ttp|p=29329956|t=2018. Herd immunity: hyperimmune globulins for the 21st century |pdf=|usr=}}''megapool for the top useful human mab''
 
{{tp|p=31351923|t=2019. (+)First clinical trial of a MERS coronavirus DNA vaccine |pdf=|usr=}}
 
{{tp|p=28664850|t=2017. (+)Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome |pdf=|usr=}}
 
{{tp|p=32373790|t=2020. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic  lymphohistiocytosis or macrophage activation syndrome |pdf=|usr=}}
 
{{tp|p=29852530|t=2020. The expanding role of mass spectrometry in the field of vaccine development |pdf=|usr=}}
 
{{tp|p=31432544|t=2020. Repurposing approved drugs on the pathway to novel therapies |pdf=|usr=}}
 
{{tp|p=31692019|t=2020. (+)Gold nanoparticle?adjuvanted S protein induces a strong antigen?specific IgG response against severe acute respiratory syndrome?related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in  lungs |pdf=|usr=}}
 
{{tp|p=24773578|t=2014. Chloroquine interferes with dengue?2 virus replication in U937 cells |pdf=|usr=}}
 
{{tp|p=32197324|t=2020. A Review on Applications of Computational Methods in Drug Screening and Design |pdf=|usr=}}
 
{{tp|p=20956884|t=2010. (+)Small Interfering RNA Effectively Inhibits the Expression of SARS Coronavirus Membrane Gene at Two Novel Targeting Sites |pdf=|usr=}}
 
{{tp|p=32317764|t=ä. Developing therapeutic monoclonal antibodies at pandemic pace |pdf=|usr=}}
 
{{tp|p=32286537|t=ä. Hydroxychloroquine: small effects in mild disease |pdf=|usr=}}
 
{{tp|p=32408071|t=2020. Relation between BCG coverage rate and COVID-19 infection worldwide |pdf=|usr=}}
 
{{tp|p=C7136957|t=ä. Is Global BCG Vaccination Coverage Relevant To The Progression Of SARS-CoV-2 Pandemic?|pdf=|usr=}}
 
{{tp|p=32388480|t=2020. Can beta-adrenergic blockers be used in the treatment of COVID-19?|pdf=|usr=}}
 
{{tp|p=32388476|t=2020. Is copper beneficial for COVID-19 patients?|pdf=|usr=}}
 
{{tp|p=32402766|t=2020. Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection |pdf=|usr=}}
 
{{tp|p=32387756|t=2020. SARS ? CoV-2: Reasons of epidemiology of severe ill disease cases and therapeutic approach using trivalent vaccine (tetanus, diphtheria and Bordetella pertussis) |pdf=|usr=}}
 
{{tp|p=32438240|t=2020. 5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection |pdf=|usr=}}
 
{{tp|p=32387320|t=ä. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients |pdf=|usr=}}
 
{{tp|p=32387333|t=ä. Could nasal nitric oxide help to mitigate the severity of COVID-19?|pdf=|usr=}}
 
{{tp|p=32387334|t=ä. The Forrest Gump approach to preventing severe COVID-19 ? reverse the predisposing pro-inflammatory state with exercise |pdf=|usr=}}
 
{{tp|p=32376359|t=2020. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32380958|t=2020. Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?|pdf=|usr=}}
 
{{tp|p=32382315|t=2020. Can graphene take part in the fight against COVID-19?|pdf=|usr=}}
 
{{tp|p=32313660|t=2020. A short review on antibody therapy for COVID-19 |pdf=|usr=}}
 
{{tp|p=32377399|t=2020. COVID-19 vaccines: breaking record times to first-in-human trials |pdf=|usr=}}
 
{{tp|p=32380200|t=2020. In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32380051|t=2020. The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence |pdf=|usr=}}
 
{{tp|p=32380052|t=2020. Granulocyte-targeted therapies for airway diseases |pdf=|usr=}}
 
{{tp|p=32389754|t=ä. (low dose radiat)RILI model and the Covid-19 pneumonia: The radiation oncologist point of view? |pdf=|usr=}}
 
{{tp|p=32387544|t=ä. Response to: Low dose radiation therapy for COVID-19 pneumonia a double-edged sword? |pdf=|usr=}}
 
{{tp|p=32409150|t=ä. An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic |pdf=|usr=}}
 
{{tp|p=32482538|t=ä. Propuesta de uso de anakinra en el distr�s respiratorio agudo secundario a COVID-19 |pdf=|usr=}}
 
 
{{tp|p=32253226|t=ä. (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice |pdf=|usr=}}
 
{{tp|p=32418730|t=ä. ?Off-label? use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers |pdf=|usr=}}
 
{{tp|p=32448638|t=2020. Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both  donors and recipients alike |pdf=|usr=}}
 
{{tp|p=32417123|t=ä. Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both  donors and recipients alike |pdf=|usr=}}
 
{{tp|p=32387409|t=ä. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A  retrospective analysis of 1061 cases in Marseille, France |pdf=|usr=}}
 
{{tp|p=32387694|t=ä. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review |pdf=|usr=}}
 
{{tp|p=32418793|t=2020. An effective CTL peptide vaccine for Ebola Zaire Based on Survivors? CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design |pdf=|usr=}}
 
{{tp|p=32381478|t=2020. Enabling emergency mass vaccination: Innovations in manufacturing and administration during a pandemic |pdf=|usr=}}
 
{{tp|p=32452420|t=2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro |pdf=|usr=}}
 
{{tp|p=32292259|t=2020. Understanding of guidance for acupuncture and moxibustion interventions on COVID-19 (Second edition) issued by CAAM |pdf=|usr=}}
 
{{tp|p=32331804|t=ä. Hydroxychloroquine and ?off-label? utilization in the treatment of oral conditions |pdf=|usr=}}
 
{{tp|p=32061923|t=2020. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions |pdf=|usr=}}
 
{{tp|p=32289478|t=2020. Statins in coronavirus outbreak: It?s time for experimental and clinical studies |pdf=|usr=}}
 
{{tp|p=28596841|t=2017. Targeting endosomal acidification by chloroquine analogs as a promising strategy  for the treatment of emerging viral diseases |pdf=|usr=}}
 
{{tp|p=32208449|t=2020. BRD4 inhibition exerts anti-viral activity through DNA damage-dependent innate immune responses |pdf=|usr=}}
 
{{tp|p=32355446|t=2020. Medicaments rhumatologiques pour le traitement de l?infection par le COVID-19? |pdf=|usr=}}
 
{{tp|p=32077621|t=2020. Glycyrrhizic?Acid?Based Carbon Dots with High Antiviral Activity by Multisite Inhibition Mechanisms |pdf=|usr=}}
 
{{tp|p=16043204|t=2005. (+)Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine |pdf=|usr=}}
 
{{tp|p=31930543|t=2020. Inactivation of three emerging viruses ? severe acute respiratory syndrome coronavirus, Crimean?Congo haemorrhagic fever virus and Nipah virus ? in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible  light |pdf=|usr=}}
 

Version vom 3. Oktober 2020, 20:18 Uhr

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

 P further streaming-in related content is here

...so calm down and enjoy the progress of immediate translational medicine:

A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
Paper is (not yet in PubMed) :

credentials to Marinus Brandl who told us about it today. based on e.g.

32408336 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
=======================================================================================
COVID19 is now a CURABLE disease !!!
=======================================================================================





Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis